Integra LifeSciences (IART) Projected to Post Earnings on Wednesday

Integra LifeSciences (NASDAQ:IART) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect Integra LifeSciences to post earnings of $0.5630 per share and revenue of $413.16 million for the quarter. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. On average, analysts expect Integra LifeSciences to post $2.39 EPS for the current fiscal year and $2.47 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $13.45 on Tuesday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The business has a 50 day simple moving average of $15.75 and a two-hundred day simple moving average of $15.52. The stock has a market capitalization of $1.05 billion, a PE ratio of -149.43, a P/E/G ratio of 0.70 and a beta of 1.21.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Truist Financial lowered their target price on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. Wells Fargo & Company set a $15.00 target price on shares of Integra LifeSciences in a report on Saturday, October 3rd. Citigroup restated a “neutral” rating and issued a $15.00 price target (down from $19.00) on shares of Integra LifeSciences in a research report on Monday, October 5th. Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, UBS Group started coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $16.71.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.